Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation Kellie A. Juradoa, Hao Wanga, Alison Slaughterb, Lei Fengb, Jacques J. Kesslb, Yasuhiro Koha, Weifeng Wanga, Alliso

Source URL: engelmanlab.med.harvard.edu

Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav

Source URL: shionogi616.tew-staging.com

• Intel Viiv
• Integrase inhibitors
• Organofluorides
• Pfizer
• Biology
• Pharmacology
• Dolutegravir
• Shionogi
• Pharmaceutical industry
• Pharmaceutical sciences
• ViiV Healthcare
• GlaxoSmithKline

Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S

Source URL: shionogi616.tew-staging.com

• Medicine
• HIV/AIDS
• Cyclopropanes
• Integrase inhibitors
• Amides
• Lamivudine
• Zidovudine
• Antiretroviral drug
• GlaxoSmithKline
• Chemistry
• Organic chemistry
• Organofluorides

Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I

Source URL: shionogi616.tew-staging.com

• Sulfonamides
• Medicine
• Carbamates
• Darunavir
• HIV/AIDS
• Antiretroviral drug
• ViiV Healthcare
• Zidovudine
• Integrase inhibitor
• Protease inhibitors
• Chemistry
• Biology

Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside

Source URL: shionogi616.tew-staging.com

• Organic chemistry
• Medicine
• Amides
• Merck
• Oxadiazoles
• Raltegravir
• Integrase
• Dolutegravir
• ViiV Healthcare
• Integrase inhibitors
• Chemistry
• Organofluorides

ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

Source URL: shionogi616.tew-staging.com

• Integrase inhibitors
• Abacavir
• Cyclopropanes
• Purines
• Antiretroviral drug
• HIV/AIDS
• Lamivudine
• Reverse-transcriptase inhibitor
• ViiV Healthcare
• Biology
• Chemistry
• Organofluorides

PDF Document

Source URL: shionogi616.tew-staging.com

• ViiV Healthcare
• Intel Viiv
• Prescription Drug User Fee Act
• Shionogi
• Integrase inhibitor
• Food and Drug Administration
• Integrase
• Pharmaceutical sciences
• Pharmacology
• Clinical research

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572)

Source URL: shionogi616.tew-staging.com

• Health
• Medicine
• Integrase inhibitors
• GlaxoSmithKline
• ViiV Healthcare
• Lamivudine
• Pfizer
• Integrase
• Raltegravir
• Organofluorides
• Chemistry
• HIV/AIDS

Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C

Source URL: shionogi616.tew-staging.com

• Enzymes
• Integrase
• Microbiology
• Virology
• ViiV Healthcare
• Intel Viiv
• Shionogi
• Dolutegravir
• HIV
• Integrase inhibitors
• Biology
• Organofluorides

PDF Document

Source URL: www.england.nhs.uk

• Integrase inhibitors
• Gilead Sciences
• Cyclopropanes
• Carbamates
• Antiretroviral drug
• Efavirenz
• Raltegravir
• Fixed-dose combination
• Reverse-transcriptase inhibitor
• Chemistry
• Organic chemistry
• Organofluorides